The Wnt5-a/ROR1 signalling axis was active in patients undergoing treatment with ibrutinib, providing an additional survival signal for CLL insensitive to BTK inhibitors, consequently limiting their capability to eradicate the disease [99]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.